Table 1.

Baseline Characteristics

	Tesamorelin (N= 28)	Placebo (N=22)
Demographics
Age (years)	[49 (46, 54)]	[53 (49, 58])
Gender-M/F (% male)	24/4 (86)	18/4 (82)
Race/Ethnicity* (N [%])
White	20 [71%]	14 [64%]
Black	6 [21%]	3 [14%]
Hispanic	1 [4%]	3 [14%]
Other	1 [4%]	2 [9%]
Smoking Status (N [%])
Never	14 [50%]	9 [41%]
Past	9 [32%]	10 [45%]
Current	5 [18%]	3 [14%]
Alcohol Use (g/day)	[0 (0, 6)]	[0 (0, 0.3)]
Duration of HIV (years)	17 ± 7	20 ± 6
Hepatitis C (N [%])	7 [25%]	5 [23%]
Medication use at Baseline
NRTI (N [%])	28 [100%]	21 [95%]
NNRTI (N [%])	14 [50%]	15 [68%]
PI (N [%])	11 [39%]	10 [45%]
Other ART (N [%])	7 [25%]	6 [27%]
Lipid lowering therapy (N [%])	13 [46%]	13 [59%]
Statin (N [%])	8 [29%]	11 [50%]
Testosterone (N [%])	7 [25%]	6 [27%]

Continuous data are presented as mean±standard deviation for normally distributed variables and median (interquartile range) for variables that are not normally distributed. No data are missing.

^*Race and ethnicity data collected via patient self-report.

Abbreviations: HIV: human immunodeficiency virus; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors; Other ART: antiretroviral therapy including entry inhibitors and integrase inhibitors